TREATMENT UPTAKE FOR HEPATITIS C INFECTION FOLLOWING AN INTERVENTION TO ENHANCE LINKAGE TO CARE AMONG PEOPLE WHO INJECT DRUGS: THE ETHOS ENGAGE STUDY

Conway A1,2, Valerio H1, Alavi M1, Silk D1, Treloar C2, Martinello M1, Milat A3, Dunlop A4,5, Murray C6, Henderson C7, Amin J8, Read P9, Marks P1, Degenhardt L10, Hayllar J11, Reid D12, Gorton C13, Lam T14, Christmass M15,16, Wade A17,18, Dore G19 and Grebely J1, on behalf of the ETHOS Engage Study Group

1 The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia
2 Centre for Social Research in Health, UNSW Sydney, Sydney, New South Wales, Australia
3 Centre for Epidemiology and Evidence, NSW Health, New South Wales, Australia
4 Hepatitis NSW, New South Wales, Australia
5 Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, New South Wales, Australia
6 Population Health Strategy & Performance, NSW Health, New South Wales, Australia
7 NSW Users and AIDS Association, NSW Health, New South Wales, Australia
8 Department of Health Systems and Populations, Macquarie University, Sydney, New South Wales, Australia
9 Kirketon Road Centre, Sydney, New South Wales, Australia
10 National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia
11 Alcohol and Drug Service, Metro North Mental Health, Metro North Hospital and Health Service, Brisbane, Queensland, Australia
12 Drug and Alcohol Service, Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia
13 Cairns Sexual Health Service, Cairns, Queensland, Australia
14 Drug Health, Western Sydney Local Health District, Sydney, New South Wales, Australia
15 Next Step Community Alcohol and Drug Service, Perth, Perth, Western Australia, Australia
16 National Drug Research Institute, Curtin University, Perth, Western Australia, Australia
17 Mid North Coast Liver Clinic, Mid North Coast Local Health District, New South Wales, Australia
18 Drug and Alcohol Services, Mid North Coast Local Health District, New South Wales, Australia

Background:
Strategies to enhance HCV testing and treatment among PWID are critical. This study evaluated HCV treatment initiation among PWID with current HCV infection following an intervention including peer connection and point-of-care HCV RNA testing.

Method:
ETHOS Engage is an observational cohort study of PWID attending 25 drug treatment clinics and needle and syringe programs (NSPs) in Australia (May 2018-September 2019). Peer workers facilitated engagement in an HCV screening intervention as people accessed services. Participants completed a questionnaire, point-of-care HCV RNA testing (Xpert® HCV Viral Load Fingerstick) and were linked to an HCV nurse/physician. As the Xpert HCV assay was not approved at time of study, results were provided to the nurse to facilitate further HCV testing/investigation. HCV treatment initiation was evaluated among participants with current HCV infection not receiving treatment at enrolment. Factors associated with not initiating treatment by the end of follow-up were assessed by logistic regression.

Results:
Among 1,443 people enrolled, 22% (n=323) had current HCV infection and were not receiving treatment. Among 323 eligible for treatment (median age, 43; 65% male), 15% were homeless, 73% were receiving opioid agonist treatment, and 70% had injected in last month. Overall, 36% (115/326) initiated treatment within 12 months and 47% (153/326) initiated treatment at any time following
enrolment (median, 6 months; range 0-28 months). Factors associated with not initiating treatment were homelessness [adjusted odds ratio (aOR):2.17; 95% confidence interval: 1.07,4.41), and injecting frequency: injecting <monthly in the last year (aOR:2.66; 1.05,6.75), and injecting >daily in the last month (aOR:3.65; 1.49,8.92) compared to no recent injecting.

Conclusion:
Treatment uptake following an HCV screening intervention including peer connection and point-of-care HCV RNA testing in drug treatment clinics and NSPs was high. People who are homeless and people with recent injecting drug use require additional support for engagement in HCV treatment.

Disclosure of Interest Statement: None